Company intelligence / Profile preview

InnovHeart

Ownership: Private
Development stage: Phase 1

Overview

InnovHeart has developed the Saturn Transcatheter Mitral Valve Replacement system for patients with mitral valve disease. The company has reported successful first-in-human trans-septal implantations and early feasibility studies with excellent hemodynamic results in initial patients. Clinical trials are ongoing in both Europe and the US.

Therapeutic areas: Cardiovascular
Modalities: Device (Transcatheter mitral valve replacement system)Biologic (prosthetic heart valve component)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Saturn

Phase 1

Indications: Mitral valve regurgitation

Partnerships

Not specified; investors include Genextra S.p.A., Panakes Partners, CDP Venture Capital, Indaco Venture Partners

Beyond the preview

Go deeper on InnovHeart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnovHeart.

Explore the full profile